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Abstract: Colorectal cancer (CRC) is one of the most common forms of cancer. Its onset from chronic
inflammation is widely accepted. Moreover, dysbiosis plays an undeniable role, thus the use of
probiotics in CRC has been suggested. They exhibit both anti- and pro-inflammatory properties and
restore balance in the microbiota. The aim of this study was to investigate the immunomodulatory
properties of six lactobacilli with probiotic features in an in vitro model of macrophage-like cells and
to test these pooled probiotics for their anti-tumour properties in a chemically induced CRC model
using Wistar male rats. Upon co-culture of M1- and M2-like macrophages with lactobacilli, cytokine
release (TNF-α, IL-1β, IL-18, IL-23) and phagocytic activity using fluorescent-labelled bacteria were
tested. The effects of orally administered probiotics on basic cancer and immune parameters and
cytokine concentration (TNF-α, IL-1β, IL-18) in colon tumours were studied. Tested lactobacilli
exhibited both pro- and anti-inflammatory properties in in vitro conditions. In vivo study showed
that the administration of probiotics was able to decrease multiplicity, volume and total tumour
numbers, restore colon length (p < 0.05) and increase IL-18 production (p < 0.05) in tumour tissue.
These data indicate both an immunomodulatory effect of probiotics on distinct macrophage subsets
and a protective effect against chemically-induced CRC.
Keywords: Lactobacillus salivarius; Lactobacillus plantarum; cytokines; immunomodulation; Wistar rat;
1,2-dimethylhydrazine
1. Introduction
Due to its metabolic activity, the human microbiota is defined as a virtual organ that consists of
more than 1013 cells, which are found lining the skin and mucosal surfaces such as the gastrointestinal
tract. The relative bacteria:human cell ratio in the literature varies from 1:1 to 10:1, nevertheless,
the biological importance of the microbiota is undeniable [1–3]. The microbiota has also been shown to
have protective and structural effects on the epithelium and is responsible for maturation of the gut
mucosal immune system [4]. On the other hand, alterations in microbial composition are associated
with many diseases, such as inflammatory bowel disease [5] and colorectal cancer (CRC) [6]. Dysbiosis
is defined as any change in commensal communities leading to an imbalance between harmless
and harmful bacterial species; such imbalances may account for either the cause or consequence
of disease [7,8]. There is, however, a strong correlation between dysbiosis and gut inflammation,
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as evidenced by a decreased proportion of Firmicutes and increased numbers of Bacteroides fragilis,
B. vulgatus and bacteria from the Fusobacterium genus [9,10]. This dysbiosis can be redressed by
probiotics, which in effect change the microbiota within the gastrointestinal tract into more favourable
species [11]. Among probiotics, lactic acid bacteria (LAB) are the most frequently used [12]. Apart
from their ability to contribute to the inhibition of pathogens [13], they have been shown to have
immunomodulatory effects [14,15].
Probiotic strains exhibit potential as dietary supplements against neoplastic transformation,
through extensive effects on the host immune system [16]. Such an investigative approach is urgently
required to identify immunomodulatory probiotic strains in the treatment of colon cancer, which
in effect support anti-tumour responses in both innate and adaptive immune cells. Innate immune
cells are highly represented in the complex ecosystem of a tumour, with macrophages being the most
abundant [17]. In addition, epithelial-associated macrophages of the gastrointestinal tract, represent
the largest population of these phagocytes in the body [18]. Generally, macrophages exist in two
distinct stages of polarisation, M1, which exhibit a pro-inflammatory phenotype, and M2, which have
an anti-inflammatory phenotype. M1s are characterised by high production of pro-inflammatory
cytokines and their induction of Th1 immune responses whereas M2s produce anti-inflammatory
mediators and drive wound healing and induce Th2 immune responses [19,20]. The M2 subset has
also been linked to tumour-associated macrophages (TAMs), especially because of their pro-tumour
angiogenic properties [21]. This polarisation of macrophage response between pro-inflammatory
M1-like and anti-inflammatory M2-like is suggested to be plastic, the manipulation of which represents
a targeted therapeutic regimen for controlling immunity to pathogens and neoplastic transformation
and cancer. The best example of this plasticity phenomenon is a growing body of evidence that
suggests that the ability of tumours to switch between macrophage phenotypes has a beneficial effect
on their own proliferation over different stages of cancer development [22,23]. Probiotics have been
shown to have both anti- and pro-inflammatory effects on macrophages [24,25], thus it is possible
that they can manipulate the plastic switching between these phenotypes in a favourable way to
tumour surveillance and protection. The role of macrophages in tumour development is complex
with dynamic macrophage phenotypic plasticity determining tumour initiation, progression and
metastasis. Generally, TAMs have a dual effect on tumour growth and progression, acting in either
a pro- or anti-tumour manner [26]. In early stage tumorigenesis, M1 macrophages may stimulate
production of pro-inflammatory mediators and cytokines, which can favour tumour cell growth.
On the other hand, M2 macrophages play a pro-tumorigenic role mainly in late stage of tumours or in
hypoxic areas, where they can promote angiogenesis, inhibit anti-tumour responses and also influence
tumour relapse after conventional anticancer therapies [27]. This M1/M2 classification however, is an
over-simplification of a functional spectrum acquired by macrophages in response to stimuli of the
tumour microenvironment. Given these key roles in homeostasis and cancer, manipulation of the
functional plasticity of colonic macrophages and their cytokine production represent an exciting
therapeutic intervention. Many macrophage-focused anticancer approaches have been investigated,
including the blockade of tumour-promotion and activation of anti-tumour effector functions [28].
Macrophage reprogramming towards an M2 anti-inflammatory subset in chronic inflammation (early
onset CRC) and an M1 tumoricidal subset post-onset CRC, represents an attractive therapeutic strategy
against cancer.
LAB Lactobacillus plantarum VD23, C28 and MS18 and Lactobacillus salivarius MS3, MS6 and
MS16 were used in the present study. These strains have been tested previously for their probiotic
features (viability under conditions of the human gastrointestinal tract, aggregation with pathogens
and lactic acid production) and showed a positive effect on animal health [29,30]. These strains were
patented as fermented foodstuff product [31]. Thus, the aim of this study was to investigate the in vitro
immunomodulatory potential of these strains via their ability to modulate macrophage subset-specific
phagocytic potential and cytokine production profiles. CRC exhibits a specific pathological sequence
progression from pro-inflammatory (M1-driven) to immunosuppressive (M2-driven) stages, thus
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the translatability of these probiotic strains was studied using a bacterial mixture, based on the fact
that some probiotic bacteria exhibit synergistic or suppressive effects on each other [32], to assess
modulation of anti-tumour responses in an in vivo model of CRC. For the further use of potential
probiotic products containing multiple strains, their benefits to the host must be confirmed for the
specified combination and not extrapolated from the evidence for the separate probiotic strains.
2. Materials and Methods
2.1. Macrophage Culture
The human monocytic cell line, THP-1, was obtained from ECACC and used for this study
between passages 7 and 35. THP-1 cells were cultured in R10 medium composed of RPMI-1640
medium supplemented with 10% (v/v) fetal bovine serum (Gibco, Massachusetts, Grand Island, NY,
USA) and 2 mM L-glutamine, in the absence of exogenously added antibiotics. Pro-inflammatory
(M1-like) macrophages and anti-inflammatory (M2-like) macrophages were generated by differentiation
of these monocytes in the presence of 25 ng/mL phorbol 12-myristate 13-acetate (PMA) for three
days or 10 nM 1,25-(OH)2-Vitamin D3 (Sigma-Aldrich, Poole, UK), for seven days, respectively [33].
M1-like macrophages were then washed and allowed to rest in fresh R10 medium without PMA for an
additional 24 h [34]. Macrophages were plated out to a final density of 5 × 105 cells/500 µL/well in R10
medium in 24 flat-bottomed well tissue culture plates.
2.2. Bacterial Culture
Lactobacilli tested in this study are shown in Table 1 and were kindly provided by Dr. Jane
Beal from internal microbiology stocks at the University of Plymouth (UK). All bacterial species were
cultured in De Man Rogosa Sharp (MRS) (Sigma-Aldrich, Poole, UK) broth at 37 ◦C, 5% CO2 for 18–20 h
until the beginning of the stationary phase. Bacterial cells were harvested by centrifugation of 4000 g
for 5 min at room temperature and resuspended in R10 medium to the desired bacterial stock density.
Table 1. The name, accession number, code and origin of lactic acid bacteria (LAB) strains tested in the
present study. The code refers to strains name used in the study.
Name. Accession Number Code Origin
Lactobacillus plantarum VD23 NCIMB 41608 VD23 isolated from the faeces of pigs [29]
Lactobacillus plantarum C28 NCIMB 41605 C28 isolated from the faeces of pigs [29]
Lactobacillus plantarum MS18 NCIMB 41607 MS18 isolated from a healthy chickensmall intestine [30]
Lactobacillus salivarius MS3 NCIMB 41606 MS3 isolated from a healthy chickensmall intestine [30]
Lactobacillus salivarius MS6 NCIMB 41609 MS6 isolated from a healthy chickensmall intestine [30]
Lactobacillus salivarius MS16 NCIMB 41610 MS16 isolated from a healthy chickensmall intestine [30]
2.3. Modulatory Effect of Live Probiotic Bacteria on Cytokine Production
To investigate probiotic regulation of macrophage cytokine release, different live bacterial strains
were added in culture to a final density of 1 × 107 CFU/mL for 18 h (determined as the optimal
concentration and time period for secretion of the cytokines TNFα, IL-1β, IL-18 and IL-23) in a
humidified environment at 37 ◦C, 5% CO2. Supernatants were harvested and stored at −20 ◦C
until assayed. Release of the pro-inflammatory cytokines, TNF-α, IL-1β, IL-18 and IL-23, were
analysed by sandwich ELISA using commercially available capture and detection antibodies for
TNF-α (BD-Pharmingen, Oxford, UK), IL-1β and IL-23 (eBioScienceTM, Paisley, UK) and an IL-18
human ELISA kit (InvitrogenTM, Paisley, UK). Protocols were followed according to the manufacturer’s
instructions and compared to standard curves, using the recognised international standards available
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from NIBSC (Potter’s Bar, UK) over the range of 7 to 5000 pg/mL for TNF-α, IL-1β, IL-18 or 16 to
2000 pg/mL for IL-23, respectively. Colorimetric development was measured by an OPTIMax tunable
microplate reader at 450 nm and analysed by Softmax Pro software, version 2.4.1 (Molecular Devices
Corp., Sunnyvale, CA, USA). Cytokine secretion results are reported as the fold of induction (FOI)
compared to the unstimulated macrophage control, to which an FOI of 1 was attributed.
2.4. Phagocytosis Assay of Live Probiotic Bacteria
To test macrophage subset phagocytosis of different bacterial strains, 5(6)-carboxyfluorescein
diacetate N-succinimidyl ester (CFSE)-loaded bacteria were used. Briefly, bacterial strains were labelled
with CFSE (Molecular Probes, Leiden, The Netherlands) at a final concentration of 1.5 mM in PBS
for 30 min in a humidified environment at 37 ◦C, 5% CO2 in the dark. Concurrently, macrophages
were treated with an inhibitor of actin polymerisation, cytochalasin D (Sigma Aldrich, Dorset, UK),
at a concentration of 1 µg/mL for 35 min at 37 ◦C, 5% CO2. After incubation, bacteria were washed
extensively to remove unbound CFSE and were added to a final density of 1 × 107 CFU/mL (determined
as the optimal concentration for phagocytosis assay) to both untreated and cytochalasin D-treated
macrophages and co-cultured in a humidified environment at 37 ◦C, 5% CO2. Phagocytosis was
performed for a period of six hours with four time points—one, two, four and six hours. Cells were
then washed with PBS, detached with trypsin and processed through flow cytometry. A total of 5000
events were recorded on a FACSAria II flow cytometer (BD Biosciences, San Jose, CA, USA). Data were
analysed with BD FACS-Diva software (BD Biosciences, San Jose, CA, USA). Degree of phagocytosis
was determined as an increase in the mean fluorescence index (MFI) ratio between untreated and
cytochalasin D-treated macrophages. Phagocytosis of each probiotic strain was carried out in triplicate
samples for at least n = 3 independent replicate experiments.
2.5. Animals and Diet
Male Wistar rats (n = 56) (Velaz, Ltd., Prague, Czech Republic) were obtained at four weeks of age
(mean body weight 130.45; range 114–157g), quarantined and housed in groups of four per cage at
room temperature 22 ± 2 ◦C, 55 ± 10% humidity and a 12 h light/dark cycle. They had free access to a
standard laboratory diet (Altromin 1324, Lage, Germany) and water. Food consumption for each cage
was monitored daily and body weights were recorded weekly. All experiments were approved by the
National Animal Ethical Committee of the Slovak Republic (license number Ro-4058/16-221) and were
conducted in accordance with the European Convention for the protection of vertebrate animals used
for experimental and other scientific purposes (ETS 123).
2.6. In Vivo Investigation of Probiotic Effects on Colorectal Cancer
After one week of acclimatisation, rats were randomly divided into four groups (Scheme 1):
control cancer group (n = 20) (DMH), probiotic-fed cancer group (n = 20) (DMH+P), probiotic-fed
healthy group (n = 8) (P) and control healthy group (n = 8) (INT). Probiotic-fed groups were given
a mixture of LAB (LP VD23, C28 and MS18 and LS MS3, MS6 and MS16) from Monday to Friday
until the end of experiment. The probiotic mixture was prepared according to standard procedure
(see Section 2.2 on bacterial culture) and administered orally in a final concentration of 109/50 µL/dose
in sterile water once a day. The proportion of bacteria in the mixture was equal. The probiotic mixture
was used as prophylactic for four weeks (prevention period) prior to 1,2-dimethylhydrazine (DMH)
administration. After the prevention period, cancer groups received subcutaneous injection of DMH.
CRC was induced by DMH (Fluka Chemie, Buchs, Switzerland) prepared according to the standard
method [35]. DMH was dissolved in 0.9% NaCl containing 1 mM EDTA and adjusted to pH 6.8 with 1
M NaOH and administered subcutaneously at 20 mg/kg once a week for 15 weeks. A fresh solution
was prepared prior to each application. Blood samples were collected monthly from the tail vein
in EDTA-containing tubes (Sarstedt, Nümbrecht, Germany) until the fifth month of the study and
analysed for leukocyte count on BC-2008 VET automatic analyser (Mindray, Shenzhen, China). At the
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age of 35 weeks, the rats were humanely euthanised by decapitation. For clarity, the experimental
design is shown in Scheme 1 below.
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2.7. Measurement of Probiotic Effects on Tumour Incidence, Colon Length and Tumour Cytokine Production
During autopsy, the colon was removed and its length was measured. It was opened along the
longitudinal axis, flushed with saline and examined macroscopically for tumours, the number, size and
distribution of which were recorded. Tumour size was measured by digital calipers and volume
calculated by the following formula V = pi ∗ L ∗W ∗H/6 (where V stands for volume, L for length,
W for width and H height) [36]. Tumours were snap frozen on dry ice and stored at−80 ◦C until analysis.
Analysis of TNF-α, IL-1β and IL-18 was performed by Bio-Plex® Multiplex Immunoassay (Bioclarma
Sr.l., Turin, Italy). Briefly, tissue samples were lysed according to the manufacturer’s instructions.
All samples were then dosed with DC Protein Assay and diluted to a working concentration of 0.9µg/µL.
Fifty µL of this solution were analysed in each well (each sample was tested in a technical duplicate).
The standard curve was optimised for lysate analysis with eight points according to manufacturer’s
instructions over the range of 10.61 to 11,327.7 pg/mL for TNF-α, 3.49 to 14,002.96 pg/mL for IL-1 β
and 3.56 to 9,048.72 for IL-18.
2.8. Statistical Analysis
All statistical analyses were performed using Minitab version 16 software (Minitab Inc., 2013,
Coventry, UK). All data were examined for normal distribution, and appropriate tests applied.
Statistical differences between groups were analysed using ANOVA followed by the Tukey post hoc
test or Kruskal–Wallis test followed by pairwise multiple comparison procedures (Mann–Whitney
test). All differences were considered statistically significant when p < 0.05.
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3. Results
3.1. In Vitro Responses of Macrophages
3.1.1. Probiotic Induction of Macrophage Cytokine Profiles was Both Strain- and Subset-Dependent
Macrophage polarisation is highly dynamic. Responding to micro-environmental cues, macrophages
can rapidly switch from one phenotype to the other. The abilities of six different lactobacilli strains to
induce TNF-α, IL-1β, IL-18 and IL-23 cytokine release from polarised macrophages were compared
(Figure 1). Lactobacilli strains differed in their ability to stimulate TNF-α production in M1 and M2
cells. In M1s (Figure 1a), three of the weakest inducers, LP VD23, MS18 and C28, differed significantly
(p < 0.001) compared to the best inducers, LS MS3 and MS6. Although strain MS16 induced TNF-α
secretion (84 FOI), it was markedly lower, compared to MS3 (740 FOI) and MS6 (400 FOI), respectively.
Different results were observed for the M2 macrophage subset (Figure 1b). All strains, except for VD23,
strongly stimulated TNF-α release (ranging from 360–1410 FOI), with the most potent inducer being
strain MS6. VD23 induction of TNF-α secretion was low in both M1 and M2 subsets, thus was not
influenced by the macrophage polarisation status. A similar trend was observed for IL-1β, especially
in M2 macrophages, where cytokine release induced by LS strains MS3, MS6 and MS16 and the LP
strain MS18 were the strongest within the panel of probiotic strains (Figure 1d). In M1s, similarly to
M2s, the LS strains (MS16, MS3, MS6) showed the highest induction of this cytokine (Figure 1c). Again,
this trend of LS strains being the highest inducers of cytokine was repeated for M1 and M2 secretion
of IL-18 (Figure 1e,f), whereas MS18, VD23 and C28 induced the smallest cytokine response. Finally,
the same strains that were good inducers of IL-1β and IL-18 secretion, emerged as potent inducers of
IL-23, regardless of macrophage subset. LP strains MS18, VD23 and C28 were poor inducers, whereas
LS strains were potent inducers of IL-23 (Figure 1g,h).
3.1.2. Phagocytic Activity of Macrophages was Strain- and Subset-Dependent
Different phagocytic activity is another important feature of macrophage polarisation. The phagocytic
index (presented as the MFI ratio) of M1- and M2-like macrophages triggered by different Lactobacillus
strains was investigated over a six-hour time course. Generally, M2-like macrophages had significantly
(p < 0.001) higher phagocytic properties against each strain immediately after the first hour of co-culture
but with a different course over six hours (Figure 2). Based on the MFI ratio at the latest time point,
the highest phagocytic activity of M2s was induced by strain VD23 (4.14 ± 1.37); M1s were significantly
less phagocytic than M2s against strain VD23 at all time points (Figure 2b). Comparing the phagocytic
properties of M1s, it can be seen that only strain MS6 induced significantly higher phagocytosis
(p < 0.01) after two hours of co-culture (1.45 ± 0.8), which increased to 3.35 ± 0.25 after 6 h (Figure 2c).
Interestingly, M1s displayed a higher phagocytic index against this strain than M2s. After four and
six hours there was even two to three-times stronger phagocytic activity in M1s than M2s (p < 0.001)
(Figure 2c). LS MS3 (Figure 2a) and MS16 (Figure 2e) induced very low phagocytic activity in both
M1s and M2s, although M2 macrophages were slightly more phagocytic (p < 0.001 and p < 0.01,
respectively). Significantly stronger phagocytic activity (p < 0.001) was observed after one, two and six
hours of co-culture of M2s with MS18, when compared to M1s (Figure 2f). LP C28 induced significantly
stronger phagocytic activity in M2s than in M1s at all time points (p < 0.001), where after four hours
the ratio for C28-treated M2s increased to 3.24 ± 0.41, apart from six hours, where the MFI ratio in M2s
dropped to the level of M1s. Phagocytic activity of C28 by M1s linearly increased over time with a
maximal index reached at six hours (Figure 2d). Finally, it can be concluded that the lowest phagocytic
activity in M1s was induced by strains MS3 and MS6 and for M2s by strain MS3. On the other hand,
the highest phagocytic activity in M1s was induced by MS6 and in M2s by VD23.
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Figure 1. Live probiotic bacteria induce distinct proinflammatory cytokine profiles. THP-1 monocytes
were differentiated into M1-like and M2-like macrophages with either 25 ng/mL PMA for three days or
10 nM 1,25-(OH)2 Vitamin D3 for seven days, respectively. M1 (a,c,e,g) and M2 (b,d,f,h) were stimulated
by live probiotic strains indicated (Lactobacillus salivarius strains MS3, MS6 and MS16; Lactobacillus
plantarum strains MS18, VD23 and C28), at a moi of 100:1 bacteria:macrophage cells for 24 h. Secretion
of the cytokines TNF-α (a and b), IL-1β (c and d), IL-18 (e and f) and IL-23 (g and h) is expressed as the
fold of induction (FOI) ratio relative to expression by the control (unstimulated macrophages), which
was set at a value of 1. Box plots represent the first to the third quartile of the data. The thick line is the
median, and the whiskers in the box plot extend to the minimal and maximal values. Data displayed is
a representative experiment with triplicate samples of n = 3 replicate experiments.
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Figure 2. acrophage phagocytosis of probiotic bacteria is strain-specific and subset-dependent.
THP-1 monocytes were differentiated into M1-like and M2-like macrophages with either 25 ng/mL
PMA for three days or 10 n 1,25-(OH)2 Vitamin D3 for seven days, respectively. M1 (triangles)
and M2 (squares) were incubated in the presence of live probiotic strains indicated, at a oi of 100:1
bacteria:macrophage cells for up to six hours in the presence or absence of 10 µg/mL cytochalasin D.
Phagocytosis was measured over a six hour time-course and expressed as the mean of the median
fluorescence intensity (MFI) ratio between macrophages and macrophages pre-treated with cytochalasin
D ± SD at one, two, four and six hours. Diagram (a) shows phagocytosis of L. salivarius strain MS3;
(b) Lactobacillus plantarum VD23; (c) L. salivarius MS6; (d) L. plantarum C28; (e) L. salivarius MS16 and
(f) L. plantarum MS18. Data displayed is a representative experiment with triplicate samples of n = 3
replicate experiments. Significant differences in phagocytosis between M1 and M2 macrophage subsets
are indicated as ** p < 0.01; *** p < 0.001.
3.2. In Vivo Anti-Tumour Effect of LAB Mixture
3.2.1. Animal Health Status
Subcutaneous injection of DMH was well tolerated, as no clinical signs of toxicity were observed.
All rats appeared healthy and gained weight throughout the experimental period (Table 2). Although
the DMH+P group showed statistically significant reduction in food consumption compared to all
other experimental groups (p < 0.001), there was no significant difference in food efficiency ratio
(FER) (Table 2). Both probiotic-fed groups did not show a significant difference in FER, suggestive
of an unaffected ability to convert food in body mass by DMH treatment in the DMH+P group.
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Moreover, colon length was significantly reduced by DMH injection and rescued upon administration
of probiotics. The probiotic-fed group did not alter the length of the colon compared to control, while
colon length in the DMH group was decreased in comparison with all groups tested (p < 0.05). Colon
length of rats in the DMH+P group did not show any significant difference compared to both P and
INT groups, whereas it demonstrated a significant increase over the DMH group, indicating that orally
administered probiotics were able to restore colon length (Table 2).
Table 2. Probiotic treatment of colorectal cancer (CRC) partially rescued DMH-induced effects on food
efficiency ratio (FER) and gut length.
Groups Body-Weight Gain (g) Food Intake (g/rat/day) FER (%) 1 Gut Length (cm)
DMH 378.6 ± 13.7 22.5 ± 0.08 A 7.67 ± 0.23 a 18.58 ± 1.04 a
DMH+P 350.3 ± 11.1 21.5 ± 0.08 B 8.09 ± 0.25 ab 21.3 ± 0.6 b
P 400.5 ± 16 23.3 ± 0.07 C 8.68 ± 0.31 b 21.5 ± 0.52 b
INT 404.6 ± 17.7 24.2 ± 0.09 D 7.78 ± 0.21 a 21.2 ± 0.52 b
All values are expressed as mean ± SEM. Means with the same superscript are not significantly different; different
superscript letters are significant, where p < 0.05 (small letters) and p < 0.001 (when superscript in capitals). 1 FER
(food efficiency ratio) (%) = (body-weight gain/food intake) ×100.
Macroscopic analysis of the colon showed a 50% tumour incidence in both DMH administered
groups (Table 3). In the DMH group, the total number of tumours was nine, while in the DMH+P
group, the number of tumours dropped to six. Moreover, average tumour volume in the DMH group
was 2.42 ± 0.56 cm3, while in the DMH+P group it was 1.66 ± 0.64 cm3. Although, these are not
significant differences, there is a trend in the reduction of multiplicity and volume after probiotic
treatment. This trend in reduced tumour involvement was further reinforced by a reduced tumour
multiplicity score and a reduction in the number of tumours observed in both the proximal and distal
colon upon probiotic treatment of DMH-administered animals.
Table 3. Effect of LAB mixture on incidence, multiplicity, number and volume of tumours in the colon
of experimental animals.
Groups TumourIncidence
Tumour
Multiplicity 1
Total
Number of
Tumours
Numbers of
Tumours in
Proximal Colon
Numbers of
Tumours in
Distal Colon
Average
Tumour
Volume (cm3) 1
DMH 4/8 (50%) 2.25 ± 1.25 9 7 2 2.42 ± 0.56
DMH+P 4/8 (50%) 1.5 ± 0.29 6 5 1 1.66 ± 0.64
P 0/8 (0%) 0 0 0 0 0
INT 0/8 (0%) 0 0 0 0 0
1 Values for tumour multiplicity and average tumour volume are expressed as mean ± SEM.
3.2.2. LAB Mixture Treatment had a Selective Effect on Tumour Tissue Secretion of Cytokines.
IL-1β, IL-18 and TNF-α are macrophage-derived cytokines that have been proven to display
pro-inflammatory activity. Mean cytokine levels in tumour tissue for both cancer groups are shown
in Figure 3. LAB treatment increased IL-1β secretion in tumour tissue whereby the DMH+P group
(460.2 ± 53.5 pg/mL) was higher than those in the cancer control (401.1 ± 56.9 pg/mL), but without
statistical significance (Figure 3a). Probiotic treatment significantly increased IL-18 production (p < 0.05)
(Figure 3b), whereas TNF-α levels were not significantly influenced (49.05 ± 3.39 pg/mL in the DMH
group and 48.66 ± 3.1 pg/mL in the DMH+P group) (Figure 3c).
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Figure 3. Probiotic treatment differentially modulated tumour IL-1β, IL-18 and TNF-α. Standardised
tumour tissue lysate obtained from DMH, untreated colorectal cancer (unshaded) and DMH+P,
probiotic treated colorectal cancer (stippled) was analysed for pro-inflammatory cytokine production by
multiplex immunoassay. IL-1β (a), IL-18 (b) and TNF-α (c) are expressed as the mean ± SEM in pg/mL,
for n = 6 tumour samples per group run in duplicate. Significant differences in cytokine production
between DMH and DMH+P are indicated as ns, not significant and * p < 0.05.
3.2.3. LAB Mixture Treatment had a Positive Effect on Leukocyte Count
Leukocyte cell count was declining with increasing age of experimental rats (Figure 4). After
the prevention period, there were no significant differences in leukocyte count between experimental
groups. Interestingly, the first significant decrease (p < 0.05) in leukocyte count was observed in
the probiotics-fed (P) group at the second blood collection time point compared to the INT group.
Administration of DMH induced a statistically significant decrease in leukocyte count after three
months of experiment (p < 0.01 vs. INT, p < 0.001 vs. DMH+P), however, probiotic feeding during
cancer progression protected animals from the leukocyte drop, not only at this blood collection time
point, but during the entire experimental period. The animals in the cancer control group (DMH) had
significantly lower leukocyte count compared to INT (p < 0.05) and DMH+P (p < 0.001) after five
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Figure 4. Leukocyte count decreased over the experimental period. Data are displayed as mean ± SEM,
n = 6 rats per group. No statistical significance was observed at 1, 2, and 4 months versus DMH group,
p < 0.001 DMH versus DMH+P, p < 0.01 DMH versus INT at the third month, and p < 0.001 DMH
versus DMH+P and p < 0.05 DMH versus INT group at the fifth month.
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4. Discussion
The purpose of this research was to investigate the beneficial effects of a novel panel and mixture
of probiotic species with respect to their immunomodulatory capacity on macrophages and their
potential to be adopted for prophylaxis of colorectal cancer, a pathology that is associated with
macrophage subset-specific effector responses. This study resulted in several important findings,
namely: (1) probiotic strains used in this study differentially induced macrophage pro-inflammatory
cytokines in a subset- and strain-specific manner, (2) phagocytosis of probiotic was both macrophage
subset- and bacterial strain-specific, (3) probiotic mix abrogates DMH-induced shortening of the colon
and exhibits a beneficial effect on leukocyte count and colon tumour development, and (4) probiotic
mix induces secretion of pro-inflammatory IL-18 by tumour tissue.
In agreement with similar studies, the probiotic bacteria tested in this study induced secretion
of pro-inflammatory, hence potentially anti-tumour cytokines (TNF-α, IL-1β, IL-18, IL-23) in a
strain-specific and cell-subset specific manner [14,37,38]. M1-like macrophages generally secreted
higher levels of TNF-α compared to M2-like (anti-inflammatory) macrophages. In the case of M1s,
strains of genus LP were 10 to 20-fold less potent than strains of LS, whereas in M2s, the LP strains C28
and MS18 induced similar levels to the LS strains, indicative of a more pro-inflammatory effect of these
bacteria on this subset of macrophage. LP VD23 was shown to have the least potent effect on secretion
of TNF-α in M2s. TNF-α, originally described for its anti-tumour properties [39], is a multifunctional
cytokine, which, at high doses, can induce tumour cell apoptosis whereas it accelerates tumour
progression via tumour invasion and metastasis with chronic low doses [40–43]. It was also found,
that TNF-α concentration increases with advanced stage of CRC [42]. The same trend was exhibited
for IL-1β production where LS strains induced 2.5 to 16-fold higher levels of this cytokine compared to
LP strains in M1-like cells. LP VD23 showed poor ability to induce secretion of this cytokine in both
macrophage subsets tested, however it must be noted that the fold induction was much higher in M2
than M1 macrophages. IL-1β can be considered as both pro- and anti-tumoral; that is, it promotes
anti-tumour responses via its pro-inflammatory nature and its ability to promote Th17 differentiation
and neutrophil activation and it is also able to drive pro-tumour responses via tumour invasiveness and
immunosuppression [44,45]. Higher IL-1β levels can induce myeloid-derived suppressor cells (MDSC),
which exhibit phenotypic similarity to anti-inflammatory M2 macrophages capable of suppressing
anti-tumour immunity, and resulting in tumour growth. MDSCs and M2 macrophages are present at
appreciable levels in many different types of cancer including CRC [46]. This would suggest that the
probiotic strain-induced cytokine profile can effectively manipulate macrophage subset plasticity and
the switching from pro-inflammatory to pro-tumour effector phenotypes. Similar results were observed
for IL-18, an IL-1β family cytokine that promotes protective host immunity mediated by CD8+ cytotoxic
T cells (Tc), NK cells [47,48] and Th1-driven macrophage activation. NK cells exhibit an anti-tumour
responses, therefore an increase in IL-18 secretion may be relevant to the anti-tumour activity of specific
lactobacilli strains in rat colorectal cancer models [49,50]. In addition, IL-18 is crucial for intestinal
epithelial cells’ (IECs) homeostasis and mucosal repair, inducing IEC proliferation/differentiation,
goblet cell mucus production, the expression of tight junction proteins and secretion of anti-bacterial
peptides [51,52] essential in preventing CRC development [53]. LS species potently induced this
cytokine in both cell subsets, whereas LP strains had little or no ability to stimulate IL-18 secretion
compared to control. Interestingly, LS MS3 induced 2.5-fold higher production of IL-18 in M2-like
cells compared to M1-like cells, which may be indicative of a subset plasticity switch towards a
pro-inflammatory/anti-tumour M1 phenotype. IL-23 is a heterodimeric pro-inflammatory cytokine,
which, in ulcerative colitis, activates and induces cytokine production of NK cells, intraepithelial
lymphocytes (IEL), innate lymphoid cells (ILCs), and Th17 (reviewed in [54]), whereas it blocks
activation of regulatory T cells (Treg) [55]. This pro-inflammatory nature however, is contradicted by
several observations where serum IL-23 levels were increased in CRC patients and positively correlated
with VEGF [56] and high primary tumour tissue levels of IL-23 were predictive of increased CRC
metastasis [57]. LS strains stimulated both macrophage subtypes to secrete this cytokine, whereas
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strain MS3 potently induced secretion of this cytokine in M2 cells. LP strains, on the other hand,
showed little or no induction of IL-23.
Differential cytokine production profiles is a key feature of polarised macrophages exhibiting
differential effector functionality, such as phagocytic capability [58,59]. Homeostatic mucosal
macrophages resemble the M2 subset, and are characterised by high phagocytic activity, scavenger
receptors (CD36, CD68, CD206) and low pro-inflammatory cytokine production, whereas
during inflammation, they polarise towards an M1-like subset (Phagolo, Scavenger Receptorlo,
Pro-inflammatory Cytokinehi) [60]. Macrophage phagocytic capability and the nature/health of
target cells being recognised for phagocytosis have a profound effect on the macrophage cytokine
profile, and hence the plasticity of the effector phenotype [61–63]. Phagocytic activity was higher in M2-
than M1-like macrophages immediately after the first hour of co-culture with all tested probiotic strains.
M1s also exhibited phagocytic activity, but at delayed onset time points. In M2-like cells, the highest
phagocytosis was observed after six hours of co-culture. In general, LS MS3 induced low phagocytic
activity in both M1s and M2s, whereas the cytokine profile stimulated by this strain in both macrophage
subsets was TNF-αhi, IL-1βhi, IL-18hi, IL-23hi. This is indicative of the potential of MS3 to drive towards
an M1 phenotype characterised by low phagocytic activity and high pro-inflammatory cytokine
expression. Lactobacillus MS6 also stimulated cytokine secretion to high levels in both macrophage
subsets, but interestingly phagocytosis in M1-like cells was the highest for all tested strains. This might
indicate that both pro- and anti-inflammatory properties are inducible by this bacterial strain and
that macrophage polarisation may be intermediate between conventional M1 and M2 subsets. MS16
potently induced pro-inflammatory cytokines whilst inducing a low to medium level of phagocytosis,
which demonstrates the pro-inflammatory potential in both M1s and M2s. Both LP strains MS18 and
C28 had poor capability to induce cytokine release and generated medium phagocytic activity in both
macrophage subsets, suggesting the more anti-inflammatory capacity of these strains. Finally, both
M1s and M2s displayed a TNF-αlo, IL-1βlo IL-18lo, IL-23lo profile after stimulation by LP VD23 whereas
M2s were Phagohi and M1s Phagomed. Of all the tested lactobacilli, this would appear to be the most
anti-inflammatory strain with potentiation of an M2 phenotype. From these data, the tested probiotic
bacteria showed pro-, anti- and mixed pro- and anti-inflammatory properties in vitro. It is however,
essential to test production of other cytokines, expression of scavenger receptors, Arg-1 and iNOS to
confirm the potential of these strains to polarise towards distinct macrophage subsets. Nevertheless,
this study has demonstrated an association between probiotic strain LS MS3 and M1 macrophage
phenotyping, whereas LP VD23 showed an association with M2 macrophage phenotype. Other
strains showed an intermediate polarising capacity between these two distinct macrophage subsets.
Consequently, these probiotic bacterial strains may differentially drive functional plasticity between
M1 and M2 macrophage subsets, effectively reprogramming macrophage effector functions towards
pro-inflammatory/anti-tumour responses or anti-inflammatory/immune suppressive responses.
As a consequence of the in vitro data, which demonstrated a range of probiotic-driven effects
such as pro-, anti- and both pro- and anti-inflammatory, and taking into account the differential
immune responses exhibited at different stages of tumour progression, the in vivo evaluation of
anti-cancer effects of probiotics on a DMH model of colon carcinogenesis utilised a mixture of the
six probiotic strains. Studies in experimental CRC models suggest that tumour infiltrating immune
cells and their inflammatory cytokines either directly or indirectly stimulate the uncontrolled growth
of cancer cells, from neoplastic transformation to tumour expansion and metastasis. The onset
and the progress of CRC could be potentially modified using a panel of lactobacilli with different
macrophage reprogramming capability. During carcinogenesis, the tested lactobacilli mix, especially
the anti-inflammatory M2-programming VD23 strain, ameliorates the inflammatory conditions (in the
early stages) and/or the pro-inflammatory M1-programming MS3 strain can boost an anti-tumour
immune response with the down-stream effect of eliminating dysplastic and cancerous cells. With
respect to long-term study of CRC, where cancer arises from chronic inflammation and leads to an
immunosuppressive state with tumour presence, a mixture of probiotic bacteria with both anti- and
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pro-inflammatory (M2- and M1-programming) features was used, and this may represent a realistic
approach to harnessing probiotic strains in the modulation of CRC.
While body weight gain over the experimental period did not differ, there was a significant
difference in daily food intake between all experimental groups. Despite the increased food intake
of the DMH group compared to the DMH+P group, the rats’ ability to convert food into body mass
(expressed by FER) was not significantly affected. The probiotic-fed group was shown to have the
highest FER, therefore it can be suggested that probiotic treatment can improve absorption and
digestion of food [64]. In general, the improved health status of probiotic-fed cancer animals was
obvious. In addition, probiotic treatment in the DMH+P group significantly increased colon length,
effectively rescuing the reduced colon length observed in the DMH group. Similar results were found
by [65], who reported that probiotic supplementation restored colon length.
Although the incidence and multiplicity of tumours were not significantly influenced by probiotic
supplementation, a trend in decreasing tumour volume and numbers in the DMH+P group compared
with cancer control was evident. The total number of tumours was 33% less for the DMH+P group,
suggesting a positive effect of probiotic treatment. Cytokine profiling in tumour tissue is a good
indicator of tumour immunity, tumour development and prognosis [66]. Probiotic treatment had no
significant effect on tumour secretion of the pro-inflammatory cytokines, TNF-α and IL-1β, whereas
IL-18 was significantly increased in tumour tissue of DMH+P animals. TNF-α and IL-1β exhibit both
pro- and anti-tumour activity in CRC, dependent on stage of progression; IL-18 however, is considered
an anti-tumorigenic cytokine, that not only affects Th1-cell-mediated immunity but also stimulates
anti-tumour activity of NK cells, thus, a probiotic-mediated augmentation of IL-18 suggests it had a
protective effect in this in vivo system. Better tumour surveillance of probiotic-fed DMH rats can be also
linked to this probiotic potential to induce IL-18 secretion, as IL-18 is critically involved in protection
against colorectal tumorigenesis [67]. Additionally, IL-18 also induces the expression of CD80, CD86,
HLA-DR and HLA-DQ on NK cells derived from cancer patients, suggesting that IL-18 conferred
NK cells on an APC-like phenotype, which indicates increased recognition and responsiveness to
tumour antigens [68]. As with TNF-α and IL-1β, IL-18 may also exhibit both pro- and anti-tumour
activity in CRC, depending on the stage of progression and immune effector cells responsive to IL-18.
It was found, that in models of IBD, secreted IL-18 potentiates IL-18 responsiveness via augmentation
of lamina propria CD4+ T cell IL-18 receptor expression and that IL-18 signalling restricts intestinal
inflammation by limiting the Th17 differentiation and promoting Treg effector responses [69].
Leukocyte count slightly decreases with age in rodents and humans [70,71]. The same trend was
also observed in the present study with a slight difference between experimental groups. Interestingly,
there was a significant decline in leukocyte count after five months of experiment in the DMH
group (p < 0.05), while leukocyte count in the DMH+P group did not change compared to the INT
group. More profound changes in peripheral leukocyte count (especially a decrease in monocytes
and lymphocytes count) can be seen in patients where disease has been systematically spread [72],
therefore these findings confirm the hypothesis that probiotics can increase quality of life or delay the
onset of the disease [73,74].
5. Conclusions
Currently there are many studies that support the notion that the microbiome shapes the immune
system, effectively modulating tumour development. Moreover, redressing the compositional and
metabolic activity dysbiosis of the gut microbiota with probiotics might reduce the risk of carcinogenesis
and cancer development. These data confirmed previous findings that each probiotic strain influences
innate immune systems in a specific manner. It is crucial to carefully assess the features of each
probiotic strain and although probiotic bacteria share some similar properties, it is desirable to avoid
generalisations. In this way it will be possible to select the most suitable candidates for therapeutic use
based on clinical signs of disease but also personalise them to specific problems in each patient. Strategies
for reshaping macrophage polarisation that assist in enhancing the anti-inflammatory activity of M2
Microorganisms 2020, 8, 387 14 of 18
macrophages in the early stages of CRC and the tumoricidal activity of M1 in the immunosuppressive
later stages, could be a promising therapeutic modality worthy of future consideration in CRC
management. Selective probiotic strains can be used prophylactically by inducing M2-driven responses
in the early stages of CRC, or by inducing anti-tumour M1-driven responses at the tumour stage of
CRC. For future studies, it is vital to test probiotics for their activity in specific stages of the disease.
It is clear, that probiotics themselves will not be able to cure cancer, but they can be used to prevent
and/or help to treat CRC by acting on the immune system and increasing the efficacy of treatments.
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